Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $3.55 per share for the quarter. Jazz Pharmaceuticals has set its FY24 guidance at $18.15-$19.35 EPS and its FY 2024 guidance at 18.150-19.350 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $109.67 on Wednesday. Jazz Pharmaceuticals has a 52-week low of $106.61 and a 52-week high of $146.70. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The business’s 50 day moving average price is $119.26 and its two-hundred day moving average price is $122.14. The firm has a market cap of $6.91 billion, a PE ratio of 17.92, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on JAZZ shares. Barclays lowered their target price on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Piper Sandler upped their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Stifel Nicolaus upped their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $195.08.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.